$39.99
-0.51[-1.26%]
At close: Apr 16
$39.99
0[0.00%]
After Hours: 9:30AM EDT
Latest News for GSK Stock (NYSE:GSK)
GSK Stock (NYSE: GSK)
Categories: All
Thursday, April 11, 2024
Thursday, April 04, 2024
- CureVac, GSK Partner Release Data On Influenza Vaccine StudyVandana Singh - Apr 4, 2024, 12:18PM
- In Heart Burn Drug Zantac's Litigation Saga, Sanofi Nears Settlement in Major Lawsuit ClusterVandana Singh - Apr 4, 2024, 9:16AM
- CureVac Announces Phase 2 Interim Data from Seasonal Influenza Vaccine Development Program in Collaboration with GSKBenzinga Newsdesk - Apr 4, 2024, 7:07AM
Tuesday, March 26, 2024
Thursday, March 21, 2024
Monday, March 18, 2024
- U.S. CDC Issues Health Alert Network Health Advisory On Increase In Global And Domestic Measles Cases And Outbreaks; Says Ensure Children In The United States And Those Traveling Internationally 6 Months And Older Are Current On MMR VaccinationBenzinga Newsdesk - Mar 18, 2024, 1:54PM
- GSK Reveals New Phase 3 Data For Jemperli Combo Therapy To Support Expanded Use Approval For Wider Endometrial CancerVandana Singh - Mar 18, 2024, 12:17PM
- Pfizer To Cut Stake In Sensodyne Toothpaste-Maker Haleon, Potentially Worth £2BVandana Singh - Mar 18, 2024, 12:08PM
- Reported Saturday, GSK Announced RUBY Phase III Data Show Potential For Jemperli (Dostarlimab-Gxly) Combinations In More Patients With Primary Advanced Or Recurrent Endometrial CancerBenzinga Newsdesk - Mar 18, 2024, 2:35AM
Monday, March 11, 2024
Thursday, March 07, 2024
- GSK's Withdrawn Multiple Myeloma Drug Shows Encouraging Combination Therapy Data In Second Late-Stage StudyVandana Singh - Mar 7, 2024, 12:18PM
- GSK shares are trading higher after the company announced results from its DREAMM-9 phase III trial of Blenrep in combination with pomalidomide plus dexamethasone verses a standard of care as a second line and later treatment for relapsed or refractory multiple myeloma.Benzinga Newsdesk - Mar 7, 2024, 12:06PM
- GSK's Headline Results From Interim Analysis Of DREAMM-8 Phase 3 Head-To-Head Trial Of Blenrep Plus Pomalidomide Plus Dexamethasone, Versus Standard Of Care As Second Line Treatment For Relapsed/Refractory Multiple Myeloma Show Trial Met Primary EndpointBenzinga Newsdesk - Mar 7, 2024, 6:33AM
Wednesday, March 06, 2024
- Injectable HIV Treatment By ViiV Healthcare Outperforms Oral Therapy, Interim Data ShowsVandana Singh - Mar 6, 2024, 5:00PM
- 10 Health Care Stocks Whale Activity In Today's SessionBenzinga Insights - Mar 6, 2024, 12:35PM
- GSK Plc - ViiV Lai Vs Oral Soc Data In Adherence-Challenged; ViiV Healthcare Announces Interim Data At CROI Indicating Superior Efficacy Of Long-Acting Injectable HIV Treatment Cabenuva; Cabenuva Demonstrated Superior Efficacy In Maintaining Viral Load Suppression Vs Daily Oral Therapy; Latitude Study Rate Of Adverse Events Was Similar In Both ArmsBenzinga Newsdesk - Mar 6, 2024, 11:04AM
Tuesday, March 05, 2024
Monday, March 04, 2024
- ViiV Healthcare Presents Phase I Clinical Trial Findings Of A Cabotegravir Long-Acting Injectable Investigational Formulation Allowing At Least 4-Months Between DosesBenzinga Newsdesk - Mar 4, 2024, 1:52PM
- Crucial Battle Over Healthcare Mandates: Biden Administration Defends Preventive Care Coverage Amidst Legal ChallengesVandana Singh - Mar 4, 2024, 11:39AM
- Guggenheim Upgrades GSK to BuyBenzinga Newsdesk - Mar 4, 2024, 5:53AM
Thursday, February 29, 2024
- Advil Maker Haleon Expects Higher 2024 Revenue After Strong 2023 Earnings, Stock SoarsVandana Singh - Feb 29, 2024, 12:45PM
- GSK Settles Another California Lawsuit On Heartburn Drug Zantac Causing Cancer, Second Within A MonthVandana Singh - Feb 29, 2024, 9:21AM
- Gsk Has Reached A Confidential Settlement With Boyd/Steenvoord, Resolving The Case Filed In California State Court, Related To Zantac (Ranitidine) The Case Was Set To Begin Trial On 2 April 2024Benzinga Newsdesk - Feb 29, 2024, 5:34AM
Wednesday, February 28, 2024
Monday, February 26, 2024
- GSK's Gepotidacin Oral Antibiotic Non-Inferior To Commonly Used Muscle-Injected Antibiotic Combo For Sexually Transmitted InfectionVandana Singh - Feb 26, 2024, 9:40AM
- GSK's EAGLE-1 Phase 3 Trial Met Its Primary Efficacy Endpoint Of Non-inferiority Comparing Gepotidacin With Intramuscular Ceftriaxone Plus Oral Azithromycin Combination Therapy For Uncomplicated Urogenital GonorrhoeaBenzinga Newsdesk - Feb 26, 2024, 5:14AM
Wednesday, February 21, 2024
Wednesday, February 14, 2024
Monday, February 12, 2024
Friday, February 09, 2024
Thursday, February 08, 2024
Tuesday, February 06, 2024
- Jim Cramer Expects Drugmaker Stock To Go 'Even Higher,' As For Kroger: 'What The Heck Is Going On?'Avi Kapoor - Feb 6, 2024, 10:56AM
- GSK Announced DREAMM-7 Phase III Trial Shows Blenrep Combination Nearly Tripled Median Progression-free Survival Versus Standard Of Care Combination In Patients With Relapsed/refractory Multiple MyelomaCharles Gross - Feb 6, 2024, 6:55AM
- The Center For Drug Evaluation Of The China National Medical Products Administration Has Accepted For Review The Regulatory Application Of GSK's Shingrix (Recombinant Zoster Vaccine) For The Prevention Of Shingles (Herpes Zoster) In AdultsBenzinga Newsdesk - Feb 6, 2024, 3:43AM
- The FDA Has Accepted Under Priority Review GSK's Application To Extend The Indication Of Its Adjuvanted Respiratory Syncytial Virus Vaccine To Adults Aged 50-59 Who Are At Increased Risk For Respiratory Syncytial Virus DiseaseBenzinga Newsdesk - Feb 6, 2024, 3:41AM
Friday, February 02, 2024
Thursday, February 01, 2024
Wednesday, January 31, 2024
- GSK Upgrades Long-Term Outlook After Q4 Performance, Shingrix Vaccine And Newly Launched RSV Vaccine ShineVandana Singh - Jan 31, 2024, 8:50AM
- GSK shares are trading higher after the company reported mixed Q4 financial results and issued guidance.Benzinga Newsdesk - Jan 31, 2024, 8:40AM
- Nasdaq Futures Plummet As Alphabet, AMD Disappointments Sour Sentiment; Spotlight Shifts To Fed Statement, Powell's PresserShanthi Rexaline - Jan 31, 2024, 7:46AM
- Earnings Scheduled For January 31, 2024Benzinga Insights - Jan 31, 2024, 6:09AM
- Recap: GSK Q4 EarningsBenzinga Insights - Jan 31, 2024, 5:05AM
- GSK Expects 2024 Turnover Growth Of 5%-7%, With Adjusted Operating Growth Of 7%-10% And Adjusted EPS Growth Of 6%-9%Benzinga Newsdesk - Jan 31, 2024, 3:38AM
- GSK Q4 Adjusted EPS $0.72 Misses $0.75 Estimate, Sales $10.00B Beat $9.61B EstimateBenzinga Newsdesk - Jan 31, 2024, 3:36AM